Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Checkpoint Therapeutics Inc CKPT

Healthcare Biotechnology
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.


NDAQ:CKPT - Post by User

Checkpoint Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(291)
•••
Post by whytestockson Dec 20, 2024 12:46pm
19 Views
Post# 36372444

Oncology Advancements Accelerate Amid Rising Early-Onset Can

Oncology Advancements Accelerate Amid Rising Early-Onset Can
NEWS: $CKPT Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses2024-12-20 12:38:47 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER &#x2013; USA News Group News Commentary &#x2013; The American Cancer Society has published its Advances in Oncology &#x2013; 2024 Research Highlights, underscoring major strides in c...CKPT - Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities